This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Navigating Changes in LDL Management: Focus on PCSK9 Inhibitors

Navigating Changes in LDL Management: Focus on PCSK9 Inhibitors

Format

Webcast

Time to Complete

1 hour

Released

March 31, 2017

Expires

March 31, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by the Academy for Continued Healthcare Learning

Commercial Supporter

This activity is supported by educational funding provided by Amgen.

Program Description

This activity features footage from a live symposium where expert faculty discuss current changes and challenges in LDL management. New therapeutic agents, including PCSK9 inhibitors and their role in the existing statin-based drug armamentarium, will be evaluated from a risk-benefit profile as an option for treating populations who may not be good candidates for statin therapy. Newly issued cholesterol guidelines for managing both LDL and HDL levels will also be evaluated, along with a comprehensive discussion of current ASCVD diagnostic criteria for various populations and risk stratifications.

As the new cholesterol practice guidelines focus on measuring and treating cholesterol and identifying whether someone already has or is at risk for ASCVD and could benefit from treatment (i.e. individualizing treatments), risk assessment is essential and needs to be performed periodically. Additionally, stratifying patients by risk allows for appropriate medical therapy (i.e. appropriate drug dosing). Statin intolerance needs to be monitored in patients, and if patients are deemed statin-resistant, alternative treatments should be appropriately utilized to mitigate CVD risk.

Intended Audience

This educational activity is designed for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, nurses, and other clinicians involved in the care and treatment of patients with dyslipidemia.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Outline available lipid guidelines and the clinical implications
  • Describe strategies to optimize lipid management in high-risk and other groups of patients to appropriately treat/mitigate CVD risk
  • Formulate individual treatment regimens in patients who have not achieved reductions in LDL-C levels despite statin therapy
  • Interpret the efficacy and safety data of available and emerging PCSK9 inhibitors and their role in current treatment paradigms

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

Faculty

Michael Davidson, MD – Activity Chair
Clinical Professor of Medicine
Director, Preventive Cardiology
The University of Chicago Medicine
Chicago, IL

Dr. Davidson discloses the following:
Merck: Consultant/advisory board
Amgen: Consultant/advisory panel, speaker's bureau, honoraria
AstraZeneca: Consultant/advisory board
Regeneron: Consultant/advisory panel, speaker's bureau, honoraria
Sanofi: Consultant/advisory panel, speaker's bureau, honoraria

Dinesh Kalra, MD, FACC
Assistant Professor
Department of Internal Medicine, Rush Medical College
Director, Advanced Cardiac Imaging
Rush University Medical Center
Chicago, IL

Dr. Kalra discloses the following:
Bayer: Advisory panel, speaker
Boehnringer Ingelheim: Advisory panel, speaker
Lundbeck: Advisory panel
Regeneron/Sanofi: Speaker's bureau
Novartis: Speaker's bureau

Peter Libby, MD
Senior Physician, Brigham and Women's Hospital
Mallinckrodt Professor of Medicine, Harvard Medical School
Boston, MA

Dr. Libby discloses the following:
DalCor Pharmaceuticals: Board Member/advisory panel
Interleukin Genetics: Board member/advisory panel
Novartis: Board member/advisory panel, research support

Staff Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

The faculty discuss investigational uses of biologics and other agents for LDL management.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

This activity will take 60 minutes to complete. To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact:
Alicia Graf
Senior Program Coordinator
agraf@achlcme.org

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue